Life Sciences Expansion Boosts Denton

Major Life Sciences Development

Novartis, a global pharmaceutical company, has chosen Denton, Texas for its newest US manufacturing facility. Bisnow reports that the company plans to construct a 46KSF plant focused on radioligand therapy, a cancer treatment the firm believes could be transformative for patient care. This new Denton site is part of Novartis’s broader $23B investment to expand its US operations, which includes research and manufacturing facilities nationwide.

Significant Local Support

To secure the project, Denton’s city council approved a $3.2M incentive package last December. The arrangement features a 50% tax abatement for 10 years, job creation grants, and a sales tax rebate for construction materials. Novartis will invest over $70M in facility improvements and plans to spend approximately $200M on equipment for the three-building property. In exchange, the company has committed to creating at least 150 advanced jobs in bioengineering, manufacturing, and operations roles.

Regional Impact and Market Growth

The Denton project highlights growing momentum in North Texas’s life sciences sector. While the region has lagged established hubs like Boston and San Francisco, its 4M SF of existing life sciences space and available land have attracted commercial real estate interest. The growing institutional appetite for life sciences real estate—now widely viewed as one of the most attractive alternative asset classes—has further fueled development and investment across emerging markets like North Texas. Local officials see Novartis’s decision as validation of the area’s potential for further population and job growth, with real estate developers watching closely for the next wave of expans